Baiyao Technology

Baiyao Technology is an AI virtual cell (AIVC) platform company founded by Li Xin, who holds affiliations with the Chinese Academy of Sciences Institute of Zoology and the Beijing Institute of Stem Cell and Regenerative Medicine and previously conducted research at MIT . Since 2023, the company has been building foundation models that use massive single-cell multi-omics data to simulate and predict cellular responses to drugs, gene editing, and environmental changes, positioning itself as a new underlying tool for drug discovery, cell therapy, and disease research .

The company has raised multiple rounds of funding within roughly a year. Its angel round in late 2025 was led by FreeS Fund with Shunxi Capital participating , followed by a new funding round in mid-2026 led by China Reform Fund's Guoxin Venture Capital with participation from the Yunqi-SJTU AI Angel Fund . FreeS Fund also made a follow-on investment in 2026 . The firm is among the portfolio companies FreeS Fund highlights in its AI for science thematic coverage .